Skip to main content

Table 4 Multivariate analysis according to baseline clinical parameters

From: Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer

 

P

Hazard ratio

95% CI

No prior gastrectomy

0.002

0.618

0.456-0.836

Two or more metastatic sites

0.347

0.831

0.566-1.222

Peritoneal dissemination

0.013

0.663

0.479-0.916

Low hemoglobin

0.002

0.740

0.610-0.896

Poor performance status

<0.001

0.375

0.245-0.574

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us